Augtyro (Repotrectinib) for Lung Cancer | MyLungCancerTeam

Connect with others who understand.

sign up Log in
About MyLungCancerTeam
Powered By

Augtyro is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer. Augtyro is also referred to by its drug name, repotrectinib.

Augtyro is a member of a class of drugs called tyrosine kinase inhibitors. Augytro is believed to work by blocking the ROS1 gene and the receptor tyrosine kinases. This inhibition helps control cancer growth and reduce tumor size.

How do I take it?
Prescribing information states that Augytyro is taken orally as a capsule once a day for 14 days, then twice daily.

Augtyro should be taken exactly as prescribed by a physician.

Side effects
The FDA-approved label for Augtyro lists common side effects including dizziness, changes to sense of taste, peripheral neuropathy, constipation, shortness of breath, poor muscle control, fatigue, muscle weakness, and problems with thinking.

Rare but serious side effects listed for Augtyro include central nervous system effects, interstitial lung disease (scarring of lungs), liver damage, muscle problems, increased blood levels of uric acid, fractures, and fetal harm.

For more details about this treatment, visit:

Augtyro (Repotrectinib) — Bristol Myers Squibb

Augtyro —

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in